CytoDyn to purchase Progenics PRO 140 anti-HIV drug
Upon successful continued clinical development of PRO 140, CytoDyn will pay subsequent milestone payments to Progenics and based on net sales upon commercialization following final FDA approval royalty
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.